Johnson & Johnson's third-quarter 2018 earnings call highlighted several positive and some mixed trends that are likely to influence the stock price in the short term:

### Positive Trends:
- **Strong Operational Performance**: The company reported a 3.6% increase in sales, with operational sales growth of 5.5%, driven by above-market growth in Pharmaceuticals and accelerating sales in Consumer and Medical Devices[1][3][4].
- **Increased Guidance**: Johnson & Johnson raised its full-year 2018 sales and adjusted EPS guidance, reflecting operational strength and confidence in their business model[1][3][4].
- **Innovation and Pipeline**: The company demonstrated strong innovation, with regulatory approvals, new product launches, and a robust pipeline, particularly in Pharmaceuticals and Medical Devices[1][3][4].
- **Global Growth**: Healthy growth was observed in emerging markets, with significant contributions from BRIC countries[4].

### Mixed Trends:
- **Currency Impact**: Although operational growth was strong, currency fluctuations had a negative impact, which could continue to affect reported sales and EPS[1][3][4].
- **Competitive Pressures**: The company faces ongoing competition in certain segments, such as biosimilar competition affecting REMICADE and generic competition impacting other products[1][3][4].
- **Pricing Pressures**: Continued pricing pressure, especially in immunology and orthopedics, could impact future growth[1][3][4].

### Conclusion:
Given the strong operational performance, increased guidance, and robust innovation pipeline, the overall outlook for Johnson & Johnson is positive. However, the short-term impact of currency fluctuations and competitive pressures might introduce some volatility.

### Rating:
**1**